Capricor Therapeutics, Inc.

The US Food and Drug Administration’s July advisory committee schedule includes a curious mix of vaccine safety reviews and the potentially triumphant return of a pulled multiple myeloma drug, in addi

The regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu

The US Food and Drug Administration heard mixed messages about what, if any, findings from two opioid analgesic product postmarketing studies should be included in labeling or communicated to patients

One-third of all the regenerative medicine advanced therapy (RMAT) designations granted by the US Food and Drug Administration’s Center for Biologics Evaluation and Research were awarded in fiscal yea